The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Open accessAbstract
SUMMARY Primary central nervous system lymphoma (PCNSL) harbors mutations that reinforce B cell receptor (BCR) signaling. Ibrutinib, a BTK inhibitor, targets BCR signaling and is particularly active in lymphomas with BCR and MYD88 mutations. We performed a proof of concept phase Ib study of ibrutinib monotherapy followed by ibrutinib plus chemotherapy (DA-TEDDi-R). In 18 PCNSL patients, 94% showed tumor reductions with ibrutinib alone, including patients having PCNSL with CD79B and/or MYD88 mutations, and 86% of evaluable patients achieved a complete remission with DA-TEDDi-R. Increased aspergillosis was observed with ibrutinib monotherapy and DA-TEDDi-R. Aspergillosis was linked to BTK-dependent fungal immunity in a murine model. PCNSL is highly dependent on BCR signaling and ibrutinib appears to enhance the efficacy of chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419
Infection in Solid-Organ Transplant Recipients
Fishman, J. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra064928 · Cited by 1,950
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,643
Self-citationOncogenically active MYD88 mutations in human lymphoma
Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S., Xiao, W., Lim, K.-H., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2011) · Nature · doi:10.1038/nature09671 · Cited by 1,512
Self-citationControl of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
Self-citationPathogenesis of Aspergillus fumigatus in Invasive Aspergillosis
Dagenais, T. R. T., & Keller, N. P. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00055-08 · Cited by 993
Abrey, L. E., Batchelor, T. T., Ferreri, A. J. M., Gospodarowicz, M., Pulczynski, E. J., Zucca, E., Smith, J. R., Korfel, A., Soussain, C., DeAngelis, L. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.524 · Cited by 914
Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Defective B cell development and function in Btk-deficient mice
Khan, W. N., Alt, F. W., Gerstein, R. M., Malynn, B. A., Larsson, I., Rathbun, G., Davidson, L., Müller, S., Kantor, A. B., Herzenberg, L. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90114-0 · Cited by 726
Cited by
Genetics and pathogenesis of diffuse large B-cell lymphoma
Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q., Roulland, S., Kasbekar, M., Young, R. M., Shaffer, A. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801445 · Cited by 2,241
Self-citationAspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400
Wright, G. W., Huang, D. W., Phelan, J. D., Coulibaly, Z. A., Roulland, S., Young, R. M., Wang, J. Q., Schmitz, R., Morin, R. D., Tang, J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.015 · Cited by 1,169
Self-citationA multiprotein supercomplex controlling oncogenic signalling in lymphoma
Phelan, J. D., Young, R. M., Webster, D. E., Roulland, S., Wright, G. W., Kasbekar, M., Shaffer, A. L., Ceribelli, M., Wang, J. Q., Schmitz, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0290-0 · Cited by 398
Self-citationImmune responses to human fungal pathogens and therapeutic prospects
Lionakis, M. S., Drummond, R. A., & Hohl, T. M. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00826-w · Cited by 379
Self-citationInhibition of Bruton tyrosine kinase in patients with severe COVID-19
Roschewski, M., Lionakis, M. S., Sharman, J. P., Roswarski, J., Goy, A., Monticelli, M. A., Roshon, M., Wrzesinski, S. H., Desai, J. V., Zarakas, M. A., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abd0110 · Cited by 357
Self-citationEffect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
Wilson, W. H., Wright, G. W., Huang, D. W., Hodkinson, B., Balasubramanian, S., Fan, Y., Vermeulen, J., Shreeve, M., & Staudt, L. M. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.006 · Cited by 315
Self-citationEarly-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib
Ghez, D., Calleja, A., Protin, C., Baron, M., Ledoux, M.-P., Damaj, G., Dupont, M., Dreyfus, B., Ferrant, E., Herbaux, C., et al. (2018) · Blood · doi:10.1182/blood-2017-11-818286 · Cited by 307
Soussain, C., Choquet, S., Blonski, M., Leclercq, D., Houillier, C., Rezai, K., Bijou, F., Houot, R., Boyle, E., Gressin, R., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.05.024 · Cited by 305
Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
Jain, P., & Wang, M. (2019) · American Journal of Hematology · doi:10.1002/ajh.25487 · Cited by 274
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Varughese, T., Taur, Y., Cohen, N., Palomba, M. L., Seo, S. K., Hohl, T. M., & Redelman-Sidi, G. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy175 · Cited by 271
Chamilos, G., Lionakis, M. S., & Kontoyiannis, D. P. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix687 · Cited by 267
Self-citationHost Control of Fungal Infections: Lessons from Basic Studies and Human Cohorts
Lionakis, M. S., & Levitz, S. M. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053318 · Cited by 209
Self-citationDepth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
Ahn, I. E., Farooqui, M. Z. H., Tian, X., Valdez, J., Sun, C., Soto, S., Lotter, J., Housel, S., Stetler-Stevenson, M., Yuan, C. M., et al. (2018) · Blood · doi:10.1182/blood-2017-12-820910 · Cited by 205
Self-citationGerminal center‐derived lymphomas: The darkest side of humoral immunity
Mlynarczyk, C., Fontán, L., & Melnick, A. (2019) · Immunological Reviews · doi:10.1111/imr.12755 · Cited by 179
The role of neutrophils in host defense against invasive fungal infections
Desai, J. V., & Lionakis, M. S. (2018) · Current Clinical Microbiology Reports · doi:10.1007/s40588-018-0098-6 · Cited by 131
Self-citationKeaney, J., Gasser, J., Gillet, G., Scholz, D., & Kadiu, I. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-019-09839-0 · Cited by 98
Metadata
- Authors
- Lionakis, M. S., Dunleavy, K., Roschewski, M., Widemann, B. C., Butman, J. A., Schmitz, R., Yang, Y., Cole, D. E., Melani, C., Higham, C. S., Desai, J. V., Ceribelli, M., Chen, L., Thomas, C. J., Little, R. F., Gea-Banacloche, J., Bhaumik, S., Stetler-Stevenson, M., Pittaluga, S., Jaffe, E. S., Heiss, J., Lucas, N., Steinberg, S. M., Staudt, L. M., & Wilson, W. H.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 31
- Issue
- 6
- Pages
- 833-843.e5
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2617968907
- Cited by
- 508
- References
- 51
- FWCI
- 33.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.